Notably, our findings revealed that C2 UBE2C+ tumour cells had stronger efferent signals in the PARs signalling pathway, and actively interacted with pericytes, fibroblasts and endothelial cells, and high expression levels of the involved signalling gene PRSS3. This evidence concerns the gene UBE2C and neoplasm.